Luminal A/B type breast cancers coexpressing ER and PR are generally more sensitive to endocrine therapy than ER alone and perhaps the “more tumoral sensitivity” maybe partly due to lessening the level of P-p38MAPK through disrupting the hormone receptor PR. This evidence concerns the gene PGR and breast cancer.